How duloxetine compares to a medication currently available for the treatment of depression in the treatment of patients with major depressive disorder.

The safety of duloxetine and any side effects that might be associated with it.

Condition	Treatment or Intervention	Phase
Depression	Drug: Duloxetine Hydrochloride	Phase IV

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• must be at least 18 years of age
• must be diagnosed with depression
• must sign informed consent

Exclusion Criteria:

• women who can become pregnant must be using birth control
• previous diagnosis of bipolar disorder, schizophrenia, or other psychotic disorder
• history of substance abuse or dependence in the last year
• patients who are suicidal
• frequent or severe allergic reactions with multiple medications

Canada, Alberta
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-295-4559) or speak with your personal physician., Calgary,  Alberta,  Canada
Canada, British Columbia
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-295-4559) or speak with your personal physician., Victoria,  British Columbia,  Canada
Canada, Nova Scotia
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-295-4559) or speak with your personal physician., Halifax,  Nova Scotia,  Canada
Canada, Ontario
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-295-4559) or speak with your personal physician., Burlington,  Ontario,  Canada
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-295-4559) or speak with your personal physician., Ottawa,  Ontario,  Canada
Canada, Quebec
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-295-4559) or speak with your personal physician., Sherbrooke,  Quebec,  Canada

Study ID Numbers:  7999
Record last reviewed:  July 2004
Last Updated:  October 13, 2004
Record first received:  August 29, 2003
ClinicalTrials.gov Identifier:  NCT00067912
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08